Selected Publications

Bod L, Kye YC, Shi J, Torlai Triglia E, Schnell A, Fessler J, Kuchroo JR, Barilla RM, Zaghouani S, Christian E, Delorey TM, Mohib K, Xiao S,Rothstein DM, Rozenblatt-Rosen O, Sharpe AH, Apetoh L, Regev A, Kuchroo V.K: B-cell specific checkpoint molecules that regulate anti-tumor immunity. Nature 619, pages348–356 (2023). 

Liu X, Liu Z, Kobayashi T, Lei PJ, Shi Y, Yuan D, Wang J, Li M, Matsui A, Mafra K, Huang P, Kuang M, Bod L, Duda DG. Inhibiting B-cell-mediated Immunosuppression to Enhance the Immunotherapy Efficacy in Hepatocellular Carcinoma. Preprint at Biorxiv (2025).

 Bod L and Shalapour S. B cells spatial organization defines their phenotype and function in cancer “Tell me with whom you consort, and I will tell you who you are”―Goethe. Current Opinion in Immunology (2024).

Revach OY, Cicerchia AM, Shorer O, Petrova B, Anderson S, Park J, Chen L, Mehta A, Wright SJ, McNamee N, Tal-Mason A, Cattaneo G, Tiwari P, Xie H, Sweere JM, Cheng LC, Sigal N, Enrico E, Miljkovic M, Evans SA, Nguyen N, Whidden ME, Srinivasan R, Spitzer MH, Sun Y, Sharova T, Lawless AR, Michaud WA, Rasmussen MQ, Fang J, Palin CA, Chen F, Wang X, Ferrone CR, Lawrence DP, Sullivan RJ, Liu D, Sachdeva UM, Sen DR, Flaherty KT, Manguso RT, Bod L, Kellis M, Boland GM, Yizhak K, Yang J, Kanarek N, Sade-Feldman M, Hacohen N, Jenkins RW. Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy. Cell Report Medicine (2025)

Schnell A, Bod L, Madi A, Kuchroo VK. (2020). The yin and yang of co-inhibitory receptors: toward antitumor immunity without autoimmunity. Cell Res, 30(4), 285-299.

Full bibliography could be found here.